Abstract：
This systematic review and meta-analysis evaluated the safety of montelukast in treating asthma during pregnancy, focusing on maternal and fetal outcomes such as congenital anomalies (CA), preterm delivery, low birthweight, spontaneous abortion, gestational diabetes mellitus, and preeclampsia. A comprehensive literature search was conducted in Google Scholar, PubMed, and the Cochrane Library databases from inception until April 30, 2024. The eligible studies assessed the safety of montelukast for asthma treatment during pregnancy. The review suggests that montelukast use during pregnancy may not significantly increase the risk of major CA. The pooled results yielded risk ratio (RR) for CA was 1.13 [95% CI (0.74, 1.73), p = 0.56, I2 = 0%]. Montelukast may be associated with preterm delivery and a low birthweight odds ratio (OR) of 1.82 [95% CI (1.35, 2.45), p < 0.001, I2 = 0%]. No significant risks were found concerning neurodevelopmental outcomes. The associations with spontaneous abortion were inconclusive [OR = 1.03, 95% CI (0.72, 1.5), p = 0.86, I2 = 73%], highlighting the need for further research. This comprehensive review underscores the importance of further investigating the safety profile of montelukast during pregnancy. While the overall findings indicate a relatively favorable safety profile, especially regarding major CA, careful consideration is needed for the potential risks of preterm delivery and low birthweight.
摘要：
本系统评价和荟萃分析评价孟鲁司特治疗妊娠期哮喘的安全性。关注母体和胎儿的结局，如先天性异常（CA），早产,低出生体重,自然流产,妊娠期糖尿病,和先兆子痫.在谷歌学者中进行了全面的文献检索，PubMed,和Cochrane图书馆数据库从成立到2024年4月30日。符合条件的研究评估了孟鲁司特用于妊娠期哮喘治疗的安全性。该审查表明，在怀孕期间使用孟鲁司特可能不会显着增加主要CA的风险。合并结果得出CA的风险比（RR）为1.13[95％CI（0.74，1.73），p=0.56，I2=0%]。孟鲁司特可能与早产和低出生体重比值比（OR）1.82相关[95％CI（1.35，2.45），p<0.001，I2=0%]。没有发现与神经发育结果有关的重大风险。与自然流产的关系尚无定论[OR=1.03，95％CI（0.72，1.5），p=0.86，I2=73%]，强调需要进一步研究。这项全面的审查强调了进一步调查孟鲁司特在怀孕期间的安全性的重要性。虽然总体结果表明相对良好的安全性，特别是关于主要的CA，需要仔细考虑早产和低出生体重的潜在风险.
